US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
about
Draft Genome Sequence of Mycobacterium abscessus BambooA new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus.Mycobacterium abscessus-Induced Granuloma Formation Is Strictly Dependent on TNF Signaling and Neutrophil Trafficking.Resistance to Thiacetazone Derivatives Active against Mycobacterium abscessus Involves Mutations in the MmpL5 Transcriptional Repressor MAB_4384.Evaluation of RGM Medium for Isolation of Nontuberculous Mycobacteria from Respiratory Samples from Patients with Cystic Fibrosis in the United States.Evaluation of Various Culture Media for Detection of Rapidly Growing Mycobacteria from Patients with Cystic Fibrosis.Comparison of Mycobacterial Growth Indicator Tube with Culture on RGM Selective Agar for Detection of Mycobacteria in Sputum Samples from Patients with Cystic Fibrosis.Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis.Year in review 2016: Interstitial lung disease, pulmonary vascular disease, pulmonary function, paediatric lung disease, cystic fibrosis and sleep.Bedaquiline inhibits the ATP synthase in Mycobacterium abscessus and is effective in infected zebrafish.An update on the pharmacotherapeutic management of lower respiratory tract infections.Patient-Centered Research Priorities for Pulmonary Nontuberculous Mycobacteria (NTM) Infection. An NTM Research Consortium Workshop ReportPulmonary Mycobacterium Avium-Intracellulare Complex Infection in an Infant: A Silent and Coincidental Finding.Practice Guidelines for Clinical Microbiology Laboratories: Mycobacteria.Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward.Mycobacterium Biofilms.Mycobacterium abscessus Smooth And Rough Morpohotypes Form Antimicrobial-Tolerant Biofilm Phenotypes But Are Killed by Acetic Acid.High levels of intrinsic tetracycline resistance in Mycobacterium abscessus is conferred by a tetracycline- modifying monooxygenase.Positive Effect of Liposomal Amikacin for Inhalation on Mycobacterium abcessus in Cystic Fibrosis Patients.The Clarithromycin Susceptibility Genotype Affects the Treatment Outcome of Patients with Mycobacterium abscessus Lung Disease.NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice.High mortality in patients with Mycobacterium avium complex lung disease: a systematic review.Determination of MIC Distribution and Mechanisms of Decreased Susceptibility to Bedaquiline among Clinical Isolates of Mycobacterium abscessus.Clinical course and significance of nontuberculous mycobacteria and its subtypes in cystic fibrosis.Minocycline Has No Clear Role in the Treatment of Mycobacterium abscessus DiseaseHydroalcoholic Extract and Ethyl Acetate Fraction of Leaves Decrease the Inflammatory Response to Subsp.
P2860
Q33815130-D434E518-EF0E-41E5-BD03-F0FCF29151C3Q36001167-C2B33CF4-4504-44A5-BE90-4C1C11C7C3D2Q36180493-96F07074-3309-46F8-A9E5-AFD5820EF1A3Q36251994-AD10B3DE-721E-4480-ADB2-1513B44E4769Q36287910-D5DF951D-A7EC-4F9D-A306-FC6047E43FA3Q37040505-C44A88C1-DC13-493D-8651-DFE38F1D7F49Q37132097-CA1C57F5-72F1-4BD2-AE64-D8047BA09E34Q39045755-E2B7A359-FC6C-4A6D-941C-7EE6B86D079AQ39329860-5CA23F06-BF46-42A6-AC92-0651C0648139Q40093529-947D4164-CB39-4206-A6B6-CCEC15CC92D1Q40222424-3086742D-767F-439E-AFFC-15323A76B258Q40540630-ADD321AD-F5AD-4C89-85C1-3F659A8C2C22Q47169129-4FB111AB-B55E-415C-89E8-F762BECCEA14Q47554066-C26926B7-F560-4452-BF69-1FCF1A21EE26Q47960948-9D88E4AF-A3DE-4426-9AEB-453DD993B57FQ49365885-4B43AB19-6186-4F67-82E8-F9687B40EDEDQ50134131-5F222659-C0B2-4C04-9231-23FEFDA4AE63Q52597956-F474B947-C96D-4CD4-AA1A-F744341DC147Q53835921-15FC621D-57EE-4DA3-BBB6-1E9F418FC492Q54943989-2F9F45E7-5D2E-482F-A1C3-2213AEE072CBQ55041894-DFF70C78-D1DF-4BBF-BFDB-52443C2988D9Q55259519-0AA75B6F-3D56-411B-87EE-AEB131FD81BFQ55439950-AF6064BA-F8E0-49D3-A10F-BBE16D10ED5BQ55510321-9F63F69D-1E50-459B-9C3E-3A38DF993EE5Q57842112-7178002E-21A7-4DA0-9C27-32352B873707Q58123809-DE069B90-7AFD-4E55-A0C5-8D9A5421DC1F
P2860
US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@ast
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@en
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@nl
type
label
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@ast
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@en
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@nl
prefLabel
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@ast
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@en
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@nl
P2093
P2860
P50
P3181
P1433
P1476
US Cystic Fibrosis Foundation ...... ic fibrosis: executive summary
@en
P2093
Bruce C Marshall
Charles L Daley
Charles S Haworth
Diana Bilton
Isabelle Sermet-Gaudelus
Jerry A Nick
Karsten Koetz
Kathryn A Sabadosa
Kenneth N Olivier
Kevin L Winthrop
P2860
P3181
P356
10.1136/THORAXJNL-2015-207983
P407
P577
2016-01-01T00:00:00Z